Albendazole
drug drugOn this page
Also known as AlbendazolAlbendazolumAlbenzaAndazolEskazoleNSC-220008SK&F 62979SK&F-62979ValbazenZentelSID11112790SID26746999SID855809SID124882632SID124882630SID144204210SID170464897SID144212617C0164450
Summary
Albendazole (CHEMBL1483) is an approved small-molecule tubulin modulator (ATC P02CA03); indicated across 17 conditions including helminthiasis and cysticercosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: P02CA03
- Indications: 17 conditions
- Clinical trials: 97
- Chemistry: 265.33 Da · C12H15N3O2S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1483 |
| Name | Albendazole |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 2082 |
| ChEBI | CHEBI:16664 |
| ATC | P02CA03 |
| Molecular formula | C12H15N3O2S |
| Molecular weight | 265.33 |
| InChIKey | HXHWSAZORRCQMX-UHFFFAOYSA-N |
SMILES: CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
IUPAC name: methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
ChEBI definition: A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations.
Pharmacological roles (ChEBI): tubulin modulator, microtubule-destabilising agent, anthelminthic drug.
Also known as: Albendazol, Albendazole, Albendazolum, Albenza, Andazol, Eskazole, NSC-220008, SK&F 62979, SK&F-62979, Valbazen, Zentel, albendazole
Patent coverage: 6,324 distinct patent families (19,005 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 16,271 (86%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, Inositol monophosphatase 1, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Beta-lactamase, Menin/Histone-lysine N-methyltransferase MLL, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 1A2, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Neuropeptide S receptor.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 14 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| LMNA | 6.4 | Potency | 398.1 | nM | CHEMBL_ACT_3667228 |
| CYP1A2 | 6.4 | AC50 | 398.1 | nM | CHEMBL_ACT_6034152 |
| MAPK1 | 6 | Potency | 1000 | nM | CHEMBL_ACT_4545737 |
| LMNA | 5.95 | Potency | 1122 | nM | CHEMBL_ACT_3649029 |
| SMN1 | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_3880220 |
| HPGD | 5.2 | Potency | 6310 | nM | CHEMBL_ACT_4800876 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| helminthiasis | 4 | MONDO:0004664 | EFO:1001342 |
| cysticercosis | 4 | MONDO:0015484 | EFO:0007231 |
13 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000764 |
| filarial elephantiasis | 3 | MONDO:0005761 | EFO:0007272 |
| onchocerciasis | 3 | MONDO:0017137 | EFO:0007402 |
| strongyloidiasis | 3 | MONDO:0005974 | EFO:0007501 |
| toxocariasis | 3 | MONDO:0005988 | EFO:0007516 |
| filariasis | 3 | MONDO:0016075 | MONDO:0016075 |
| parasitic infectious disease | 3 | MONDO:0005135 | EFO:0001067 |
| malaria | 3 | MONDO:0005136 | EFO:0001068 |
| hookworm infectious disease | 2 | MONDO:0005799 | EFO:0007314 |
| trichuriasis | 2 | MONDO:0005996 | EFO:0007524 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| ocular onchocerciasis | 2 | MONDO:0005878 | EFO:0007398 |
| intestinal disorder | 1 | MONDO:0005020 | EFO:0009431 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 97.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 35 |
| PHASE3 | 19 |
| PHASE4 | 18 |
| PHASE2 | 17 |
| PHASE2/PHASE3 | 5 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06376396 | PHASE4 | NOT_YET_RECRUITING | Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis |
| NCT07074444 | PHASE4 | RECRUITING | Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel |
| NCT00222547 | PHASE4 | COMPLETED | Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6 |
| NCT00659997 | PHASE4 | COMPLETED | Efficacy Albendazole and Levamisole Against STH on Unguja |
| NCT01087099 | PHASE4 | COMPLETED | A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children |
| NCT01192802 | PHASE4 | COMPLETED | Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora |
| NCT01327469 | PHASE4 | COMPLETED | The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia |
| NCT01748929 | PHASE4 | COMPLETED | Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth |
| NCT01903057 | PHASE4 | WITHDRAWN | Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis |
| NCT02005653 | PHASE4 | COMPLETED | Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection |
| NCT02397772 | PHASE4 | COMPLETED | Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya |
| NCT02597556 | PHASE4 | WITHDRAWN | The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children |
| NCT02641210 | PHASE4 | COMPLETED | Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin |
| NCT02675140 | PHASE4 | COMPLETED | Effect of Hookworm Elimination and Vitamin A Intervention on Iron Status of Preschool Children in Sichuan, China |
| NCT03032042 | PHASE4 | WITHDRAWN | Intestinal Microbiome Post-Azythromycin/Albendazole Treatment |
| NCT03036059 | PHASE4 | COMPLETED | Twice Yearly Treatment for the Control of LF |
| NCT03278431 | PHASE4 | COMPLETED | Triple Combinations Against Hookworm Infections in Lao |
| NCT04391998 | PHASE4 | UNKNOWN | Parasitic Infection in Anemic Pregnant Women |
| NCT06613997 | PHASE3 | NOT_YET_RECRUITING | 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia |
| NCT07159373 | PHASE3 | NOT_YET_RECRUITING | Better Options for Lymphatic Filariasis Treatment |
| NCT00002191 | PHASE3 | COMPLETED | A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis |
| NCT00133458 | PHASE3 | WITHDRAWN | RCT ALB for SA Cysticercosis |
| NCT00283699 | PHASE3 | COMPLETED | A Pilot Study of Neurocysticercosis Treatment |
| NCT00290823 | PHASE3 | COMPLETED | Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients |
| NCT00396500 | PHASE3 | COMPLETED | Deworming and Vitamin A (DEVTA) Prepilot Study |
| NCT00441285 | PHASE2/PHASE3 | COMPLETED | Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) |
| NCT00755560 | PHASE3 | UNKNOWN | Treatment of Asymptomatic Toxocariasis With Albendazole in Children |
| NCT00765024 | PHASE3 | COMPLETED | Ivermectin Versus Albendazole for Chronic Strongyloidiasis |
| NCT01722539 | PHASE3 | COMPLETED | Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren |
| NCT01825031 | PHASE3 | COMPLETED | Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy |
| NCT02509481 | PHASE2/PHASE3 | COMPLETED | Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study |
| NCT02725255 | PHASE2/PHASE3 | COMPLETED | Design and Clinical Evaluation of a School Meal With Deworming Properties |
| NCT02947581 | PHASE3 | TERMINATED | Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) |
| NCT03014167 | PHASE3 | COMPLETED | Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) |
| NCT03238131 | PHASE3 | COMPLETED | IVM Alone vs ALB + IVM Against Onchocerciasis |
| NCT03474276 | PHASE3 | COMPLETED | Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old |
| NCT03527732 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of IVM/ALB Co-administration |
| NCT04311671 | PHASE3 | COMPLETED | Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole |
| NCT04410406 | PHASE3 | COMPLETED | Moxidectin for LF, Cote d’Ivoire (DOLF) |
| NCT04966702 | PHASE3 | COMPLETED | Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) |
| NCT05124691 | PHASE2/PHASE3 | TERMINATED | Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms |
| NCT06188715 | PHASE3 | COMPLETED | Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC |
| NCT03435718 | PHASE2 | NOT_YET_RECRUITING | Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults |
| NCT04713787 | PHASE2 | RECRUITING | A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults |
| NCT06070116 | PHASE2 | ACTIVE_NOT_RECRUITING | Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis |
| NCT07045493 | PHASE2 | ENROLLING_BY_INVITATION | Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh |
| NCT07258173 | PHASE2 | NOT_YET_RECRUITING | Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita |
| NCT00339417 | PHASE2 | COMPLETED | Effect of Albendazole Dose on Clearance of Filarial Worms |
| NCT00375583 | PHASE2 | COMPLETED | Effect of Albendazole Dose on Clearance of Filarial Worms |
| NCT00511004 | PHASE2 | COMPLETED | Effect of Albendazole Dose on Treatment of Lymphatic Filariasis |
| NCT01019083 | PHASE1/PHASE2 | COMPLETED | Studies of Immune Responses to Orally Administered Vaccines in Developing Country |
| NCT01975441 | PHASE2 | COMPLETED | Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa |
| NCT02636803 | PHASE2 | WITHDRAWN | Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults |
| NCT03172975 | PHASE2 | COMPLETED | Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection |
| NCT03527745 | PHASE2 | COMPLETED | Albendazole Dose Finding and Pharmacokinetics in Children and Adults |
| NCT03664063 | PHASE2 | COMPLETED | PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) |
| NCT03950037 | PHASE2 | WITHDRAWN | SANCC: Clinical Trial Early Intervention |
| NCT04041453 | PHASE2 | COMPLETED | Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients |
| NCT04913610 | PHASE2 | TERMINATED | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection |
| NCT05538767 | PHASE2 | COMPLETED | Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm |
| NCT01755637 | PHASE1 | COMPLETED | Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population |
| NCT06201559 | PHASE1 | COMPLETED | Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions |
| NCT05949190 | Not specified | ACTIVE_NOT_RECRUITING | Improving Cognition and Gestational Duration With Targeted Nutrition |
| NCT06265870 | Not specified | RECRUITING | Specific Versus Empirical Anthelminthic Treatment in Eosinophilia |
| NCT00004403 | Not specified | COMPLETED | Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis |
| NCT00130910 | Not specified | COMPLETED | Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation |
| NCT00215280 | Not specified | COMPLETED | Epidemiology and Control of Mansonella Perstans Infection in Uganda |
| NCT00344669 | Not specified | COMPLETED | Effect of Mass Deworming on Child Growth |
| NCT00347113 | Not specified | COMPLETED | Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania |
| NCT00367627 | Not specified | COMPLETED | Relative Efficacy of Two Regimens of Ante-helminthic Treatment |
| NCT00507221 | Not specified | COMPLETED | Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression |
| NCT00817713 | Not specified | TERMINATED | Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa? |
| NCT00857116 | Not specified | COMPLETED | Deworming Against Tuberculosis |
| NCT01050374 | Not specified | COMPLETED | Safety and Efficacy of Drug Combinations Against Schistosomiasis |
| NCT01050452 | Not specified | COMPLETED | Safety and Efficacy of Drug Combinations Against Trichuris Trichiura |
| NCT01050517 | Not specified | COMPLETED | Safety and Efficacy of Drug Combinations Against Triple Infections |
| NCT01070277 | Not specified | UNKNOWN | Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea |
| NCT01213576 | Not specified | TERMINATED | Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi |
| NCT01308268 | Not specified | UNKNOWN | Management of Soil-transmitted Helminthiasis and Strongyloidiasis |
| NCT01395381 | Not specified | WITHDRAWN | Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition |
| NCT01440608 | Not specified | COMPLETED | Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy |
| NCT01541631 | Not specified | UNKNOWN | A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes |
| NCT01658774 | Not specified | COMPLETED | Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children |
| NCT01905423 | Not specified | COMPLETED | Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis |
| NCT02102321 | Not specified | UNKNOWN | Does Treating Hookworm Improve Productivity of Small Subsistence Farmers |
| NCT02253095 | Not specified | COMPLETED | Combined Package of Interventions for Environmental Enteropathy |
| NCT02351687 | Not specified | COMPLETED | Package of Interventions After Recovering From Moderate Acute Malnutrition |
| NCT02420574 | Not specified | COMPLETED | Assessment of Drug Efficacy of Local Albendazole |
| NCT02812615 | Not specified | UNKNOWN | The Bangladesh Environmental Enteric Dysfunction Study |
| NCT02974049 | Not specified | COMPLETED | Lymphatic Filariasis (LF) in Ivory Coast |
| NCT03079388 | Not specified | COMPLETED | Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi) |
| NCT03155035 | Not specified | COMPLETED | Effect of Routine Deworming on Weight of Children |
| NCT04041427 | Not specified | COMPLETED | Urine Albendazole Levels for Coverage Assessment |
| NCT05354258 | Not specified | UNKNOWN | Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children |
| NCT05453045 | Not specified | UNKNOWN | Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva |
| NCT06483880 | Not specified | UNKNOWN | The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection |
| NCT06497075 | Not specified | COMPLETED | Co-administration of IVM and ALB in School-based Deworming in Uganda |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: helminthiasis, cysticercosis
- In clinical trials for: HIV infectious disease, filarial elephantiasis, onchocerciasis, strongyloidiasis, filariasis, parasitic infectious disease, malaria, hookworm infectious disease, trichuriasis, severe acute respiratory syndrome, ocular onchocerciasis